Life science company focused on solving Duchenne muscular dystrophy
Location: United States, Massachusetts, Cambridge
Total raised: $50M
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | RA Capital... | racap.com |
| - | Perceptive... | perceptive... |
| - | Bain Capit... | baincapita... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.03.2017 | Series C | $50M | - |
Mentions in press and media 16
| Date | Title | Description |
| 24.09.2025 | Kinea Bio Receives Up To $1.1M Commitment From Jain Foundation | Kinea Bio, a Seattle, WA-based biotechnology company dedicated to developing transformative genetic medicines, received up to $1.1M commitment from Jain Foundation. The company intends to use the funds to support key IND-enabling activities... |
| 01.04.2025 | S&P, Nasdaq post big quarterly percentage drops on Trump tariff turmoil | S&P, Nasdaq post big quarterly percentage drops on Trump tariff turmoil By David FrenchApril 1, 202512:09 AM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link SummaryCompanies S&P, Nasdaq pos... |
| 13.03.2024 | Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results | - |
| 07.03.2024 | Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD | - |
| 06.03.2024 | Solid Biosciences to Participate at Upcoming Investor Conferences | - |
| 22.02.2022 | Tenth Annual Lake Nona Impact Forum Convenes Health And Wellbeing Thought Leaders In Orlando, Florida | Deepak Chopra speaks during the Lake Nona Impact Forum “There’s no doubt we live in a different world since the arrival of COVID-19,” said Impact Forum Co-Founder Gloria Caulfield. “This year’s Impact Forum is critical as we gather some of ... |
| 27.10.2021 | Public-private partnership launched to accelerate gene therapies for rare diseases | The National Institutes of Health and U.S. Food and Drug Administration unveiled a public-private partnership Wednesday aimed at accelerating gene therapies for the roughly 30 million Americans living with a rare genetic disease. “They’ve w... |
| 23.10.2020 | Ultragenyx injects $40M to grab Solid's microdystrophin transgene — while sidestepping the AAV9 vector that stirred up safety fears | Since before Ilan Ganot started Solid Bio to develop a gene therapy for kids like his son, who has Duchenne muscular dystrophy, Ultragenyx CEO Emil Kakkis has been watching and advising the former investment banker as he... |
| 26.07.2019 | EMA backs five medicines; Solid Bio raises $60M in private placement | → The European Medicines Agency on Friday recommended five new medicines for approval, including Bayer’s cancer drug Vitrakvi — the site-agnostic cancer drug was given a speedy approval by the FDA in late 2018 — and GW... |
| 26.01.2018 | Solid Biosciences Announces Initial Public Offering Pricing | Solid Biosciences Inc. (NASDAQ:SLDB), a Cambridge, Mass.-based life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD), announced the pricing of its initial public offering of 7,812,500 shar... |
Show more